CD19 and neoplasm: Thus secreted bridging proteins should be biased to accumulate only where cell and antigen density is most abundant, ie. in the tumor itself, and should therefore primarily mediate activation of a CAR-CD19 T cell when bridging to an antigen-positive tumor cell.